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Abstract
Background: It has been suggested that outcomes of antidepressant treatment for major depressive disorder could be
significantly improved if treatment choice is informed by genetic data. This study aims to test the hypothesis that common
genetic variants can predict response to antidepressants in a clinically meaningful way.
Methods and Findings: The NEWMEDS consortium, an academia–industry partnership, assembled a database of over 2,000
European-ancestry individuals with major depressive disorder, prospectively measured treatment outcomes with serotonin
reuptake inhibiting or noradrenaline reuptake inhibiting antidepressants and available genetic samples from five studies
(three randomized controlled trials, one part-randomized controlled trial, and one treatment cohort study). After quality
control, a dataset of 1,790 individuals with high-quality genome-wide genotyping provided adequate power to test the
hypotheses that antidepressant response or a clinically significant differential response to the two classes of antidepressants
could be predicted from a single common genetic polymorphism. None of the more than half million genetic markers
significantly predicted response to antidepressants overall, serotonin reuptake inhibitors, or noradrenaline reuptake
inhibitors, or differential response to the two types of antidepressants (genome-wide significance p,561028). No biological
pathways were significantly overrepresented in the results. No significant associations (genome-wide significance
p,561028) were detected in a meta-analysis of NEWMEDS and another large sample (STAR*D), with 2,897 individuals in
total. Polygenic scoring found no convergence among multiple associations in NEWMEDS and STAR*D.
Conclusions: No single common genetic variant was associated with antidepressant response at a clinically relevant level in
a European-ancestry cohort. Effects specific to particular antidepressant drugs could not be investigated in the current
study.
Please see later in the article for the Editors’ Summary.
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Introduction
Major depressive disorder (MDD) is a disabling illness, affecting
a high proportion of individuals at some point in their life [1].
Prescription of antidepressants is the most common initial step in
treating MDD, but less than half of individuals achieve remission
of symptoms with their first antidepressant [2,3]. It has been
proposed that common genetic variants could be used to
personalize psychiatric treatment and significantly improve
outcomes [4–7]. However, to date there has not been a robust,
well-replicated finding of sufficient effect size to be worth
translating into a clinical setting.
Identification of genetic determinants of antidepressant response
has the potential to improve the treatment of MDD in two
important ways. First, genetic and molecular predictors of poor
treatment outcome with available antidepressants can provide
targets for the development of novel therapeutic agents that may
be effective for the type of depression that is resistant to current
treatments. Second, for many individuals with MDD, delay in
reaching recovery is avoidable, since they have the potential to
respond to one of the currently available treatments. If a predictor
of differential outcome with alternative treatments is identified, a
clinician could use it to select the antidepressant that is most likely
to alleviate depression in a given individual. For both applications,
the clinical implications are predicated on the effect size of the
prediction. A consensus criterion has been set for what size of
difference in depressive symptoms is clinically meaningful: a panel
of experts and service users has concluded that a difference in
outcome equal or greater than three points on the Hamilton
Rating Scale for Depression is noticeable to the patients and their
relatives and can be considered as clinically significant [8,9]. This
criterion is equal to 6.33% of variance in outcome explained,
which can be applied to assess whether a genetic biomarker
provides clinically significant prediction [9]. Currently, no
clinically significant predictor is available [10]. The aims of this
NEWMEDS study address the two potential avenues for using
genomic information to improve treatment of depression.
The first aim is to identify common genetic polymorphisms that
predict unfavourable outcome of treatment with currently
available antidepressants. Addressing this issue in the large
combined NEWMEDS sample will substantially expand on the
evidence from the first genome-wide studies on outcomes for
single-drug treatment [11] or naturalistic inpatient treatment [12]
of depression and could provide novel targets for the development
of new treatments.
The second aim is to obtain predictors of differential outcomes
of treatment with antidepressants with different modes of action in
the largest comparative pharmacogenetic study to date. Specifi-
cally, we aim to identify common genetic variants that differen-
tially predict outcome of treatment with antidepressants that act
primarily through the inhibition of serotonin reuptake (serotonin
reuptake inhibitors [SRIs]) or act primarily through the inhibition
of norepinephrine reuptake (noradrenaline reuptake inhibitors
[NRIs]). For the first time, to our knowledge, these two aims will
be pursued in a sample that is large enough to provide sufficient
power to ensure interpretable results.
Methods
Samples
As part of the NEWMEDS consortium (http://www.newmeds-
europe.com) [13], three studies conducted by academic institutions
(GENDEP, a part-randomized open study of two active
antidepressants, n= 868; GENPOD, a randomized controlled trial
of two active antidepressants, n= 601; and GODS, a treatment
cohort of severe depression, n= 131) [14–16] and two studies by
pharmaceutical industry members of the European Federation of
Pharmaceutical Industries and Associations (active comparator
arms from randomized controlled trials by Pfizer, n= 355, and
GlaxoSmithKline, n= 191) were combined to obtain a sample of
2,146 adult individuals (1,205 women and 941 men; see Table 1 in
Text S1 for description by contributing study) diagnosed with
unipolar MDD according to the Diagnostic and Statistical Manual
of Mental Disorders–IV and the International Classification of
Diseases–10, with prospective data on outcome of treatment with
SRI or NRI antidepressants. Diagnoses of schizophrenia,
schizoaffective disorder, or bipolar disorder, or current alcohol
or drug dependence constituted exclusion criteria. All individuals
were treated for 6 to 12 wk with either an antidepressant that acts
primarily through blocking the reuptake of serotonin (SRIs:
escitalopram, citalopram, paroxetine, sertraline, fluoxetine) or an
antidepressant that acts primarily through blocking the reuptake of
norepinephrine (NRIs: nortriptyline, reboxetine). These groupings
are based on previous evidence that at least some genetic
predictors of treatment response are specific to antidepressants
that block serotonin or noradrenaline reuptake [14]. The two
largest studies (GENDEP and GENPOD) included an open-label
randomized comparison between an SRI (escitalopram, citalo-
pram) and an NRI (nortriptyline, reboxetine). Detailed informa-
tion on individual studies, including inclusion and exclusion
criteria for each study, can be found in Text S1 (section 1.1).
Genotyping
From each study, individuals with self-reported white European
ancestry, available high-quality blood DNA samples, and valid
information on treatment outcome with either an SRI or an NRI
were selected for genotyping.
Samples were genotyped on Illumina Human610-Quad Bead-
Chips (n= 727) or Illumina Human660W-Quad BeadChips
(n= 1,166), which have identical tag SNP coverage. More
specifically, 727 samples from the GENDEP study were genotyped
at the Centre National de Ge´notypage (Evry Cedex, France) using
the Illumina Human610-Quad BeadChip and were subjects of
previous reports [17,18]. The GENPOD, GlaxoSmithKline,
Pfizer, GODS, and 93 additional GENDEP samples were
genotyped at the University of Geneva Medical School (Geneva,
Switzerland) using the Illumina Human660W-Quad BeadChip for
the NEWMEDS consortium.
Quality Control
Quality control was implemented in PLINK [19], first on the
level of the genetic marker and then on the level of the individual.
Markers with minor allele frequency over 0.01 and at least 97%
complete genotyping were retained. To avoid batch artefacts,
markers that differed significantly (p,161023) by genotyping
centre were excluded. Overall, 520,978 (99.0%) of the 526,424
genotyped SNPs passed all stages of quality control and were
included in pharmacogenetic analyses. Hardy–Weinberg equilib-
rium was tested, but was not used as an exclusion criterion for
markers, since departures from Hardy–Weinberg equilibrium are
expected in a case-only study [20].
Individuals were excluded for ambiguous sex (genotypic sex
different from phenotypic sex) (n= 22), abnormal heterozygosity
(n= 16), cryptic relatedness up to third-degree relatives by identity
by descent (n= 20), genotyping completeness less than 97% (n= 9),
and non-European ethnicity admixture detected as outliers in
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iterative EIGENSTRAT analyses of a linkage-disequilibrium-
pruned dataset (n= 35). One additional individual was excluded
because of invalid phenotypic information, leaving 1,790 (94.6%) of
the 1,893 genotyped individuals for the pharmacogenetic analyses.
Figure 1 shows the flow of individuals through genotyping and
quality control.
Definition of Antidepressant Response Phenotype
Response to antidepressants involves changes in depressive
symptoms over a number of weeks and is more accurately
captured by continuous than by dichotomous variables [17,21–
23]. We defined response as a continuous variable, reflecting
proportional reduction in depression severity from baseline to end
of treatment. This measure is uncorrelated with initial severity
(20.10,r,0.10 in all component studies), is independent of
depression rating scale used, and is clinically relevant since it
closely reflects clinician’s impression of improvement [17,24].
Studies included in NEWMEDS used several outcome mea-
sures. The Montgomery–A˚sberg Depression Rating Scale [25] was
the primary outcome measure in GENDEP and GODS, the 17-
item Hamilton Rating Scale for Depression (HRSD-17) [26] was
the primary outcome measure in the studies conducted by Pfizer
and GlaxoSmithKline, and the Beck Depression Inventory [27]
was the primary outcome measure in GENPOD. While the
outcome measures used differ in details, here we are interested in
generalizable effects related to depression as a whole rather than
effects specific to a particular measure. Previous research has
shown no difference between classes of antidepressants in response
as measured by these three scales [28]. In addition, we took the
following steps to minimize the effects of scale differences. To
allow for an unbiased analysis of the combined dataset, we
converted the outcome measures within each study to a single
continuous metric: a standardized change score, adjusted for sex,
age, and recruitment centre within each contributing study. The
adjusted change score was z-transformed within each study to
remove any correlation between data origin and outcome prior
to the genetic analysis, and to remove effects that are specific to
individual contributing studies. Detailed information about the
definition of the phenotype is provided in Text S1 (section 1.3).
Statistical Analysis
Data analysis was carried out according to a protocol specified
prior to data acquisition (Text S2). Joint analysis of individual-level
data was conducted to allow for rigorous quality control and to
retain maximum statistical power when combining studies that
varied in size. The whole sample was analyzed jointly since this is a
more efficient and powerful approach than discovery–replication
design [29,30]. Quality-controlled genotypes were tested for
Figure 1. Flow of samples through quality control.
doi:10.1371/journal.pmed.1001326.g001
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association with the adjusted percentage change in depression
severity using linear regression under an additive genetic model in
PLINK [19]. Four genome-wide analyses were performed. A first
linear regression searched for common genetic markers that
predict response to both types of antidepressants in the whole
sample of 1,790 individuals. The second and third analyses tested
predictors of response to SRIs (n= 1,222) and NRIs (n= 568). A
fourth analysis, of primary interest to our second aim, searched the
genome for common variants that differentially predict response to
SRIs and NRIs. To avoid confounding by covariation between
antidepressant drug and genetic background due to different
studies contributing unequal numbers of individuals to each
antidepressant group, we tested this hypothesis as a drug-by-
genotype interaction in a sample restricted to individuals that were
randomly allocated to treatment with either an SRI or an NRI
(n= 949), thus ensuring full comparability of the two drug groups
on measured and unmeasured confounders. In all analyses, the
influence of genetic population structure was controlled by the
inclusion of the four significant principal components from the
final iteration of the EIGENSTRAT analysis of linkage-disequi-
librium-pruned genetic data. We defined genome-wide statistical
significance at the generally accepted threshold p,561028 [31].
Associations reaching a less stringent threshold of p,561026
are reported in Text S1 (section 2). Analyses performed by
component study, summary data meta-analysis (Text S1, section
6), and pharmacogenetic associations within genes reported in
previous candidate gene and genome-wide studies (Text S1,
section 7) are also provided.
Power Analysis
Our aim was to determine whether any common genetic variant
predicts a clinically significant difference in the outcome of
treatment with antidepressants, taking a difference of at least three
points in the reduction of depression symptom severity on HRSD-
17 as the benchmark for clinical significance [8]. Specifically, we
aimed to achieve 80% power to detect an additive genetic effect that
explains 6.33% of variance in outcome, corresponding to an
HRSD-17 three-point difference in a drug comparison study [9].
Since not all common genetic variants were directly genotyped, we
factored in imperfect tagging (at R2 = 0.8) to estimate power for
detecting effects of genotyped and ungenotyped variants. The
quality-controlled sample provided a power well above 80% to
detect a clinically significant effect at the genome-wide significance
level for three of the four analyses (overall, SRI, and genotype–drug
interaction). The meta-analysis of NEWMEDS and STAR*D
samples had an adequate power to detect even an effect that was
half of what would be considered clinically significant. Details of the
power analysis can be found in Text S1 (section 1.4).
Pathway Analysis
Enrichment of genome-wide association signal in genes that
belong to known biological pathways was tested using ALIGA-
TOR [32]. This method takes a predefined list of significant SNPs,
and tests whether these SNPs cluster in genes belonging to a
particular pathway more than would be expected by chance,
allowing for varying numbers of SNPs per gene and non-
independence of SNPs within and between genes. ALIGATOR
corrects the significance levels of pathway-specific enrichment for
the testing of multiple non-independent pathways. Further details
of the pathway analysis can be found in Text S1 (section 3).
Meta-Analysis with STAR*D
A meta-analysis was undertaken between NEWMEDS and data
subsequently obtained from the first level of the STAR*D
(Sequenced Treatment Alternatives to Relieve Depression) trial,
when all participants with MDD were treated with citalopram (an
SRI), in the hope of finding genome-wide significant associations.
For further information about the STAR*D sample, genotyping,
and quality control procedures see Text S1 (section 4.1).
To maximize the overlap between the two samples and genome
coverage, both NEWMEDS and STAR*D were imputed to
include over 1.4 million markers using BEAGLE 3.3 [33] and the
HapMap phase 3 CEU population as the reference dataset. Meta-
analysis was undertaken using the meta command in PLINK [19]
in the entire samples and in a sample limited to individuals treated
with a serotonergic antidepressant. More information about these
methods used can be found in Text S1 (section 4).
Polygenic Scoring
While both our main analysis in NEWMEDS and the meta-
analysis with STAR*D had sufficient power to detect clinically
significant genetic associations, there could also exist an underlying
weak signal from across the genome that could offer insight into
the mechanism of antidepressant response. The methodology of
polygene scoring allows for the detection of such weakly
distributed signal [34]. Details on this method can be found in
Text S1 (section 5). Polygenic scores were created based on the
NEWMEDS results and used to predict outcomes in STAR*D
using linear regression. Two polygenic tests, one based on the
entire NEWMEDS sample and the other restricted to SRI-treated
participants, were carried out.
Results
Response to Any Antidepressant
Linear regression assessed the influence of 520,978 SNPs on the
adjusted percentage change in depression severity in the whole
sample of 1,790 antidepressant-treated individuals. A quantile–
quantile plot showed a uniform distribution of p-values, with no
inflation of the test statistic (median lambda = 1.0034; Figure 2).
No association reached the genome-wide level of significance
(Figure 3).
Response to Serotonergic Antidepressants
A linear regression tested association between 520,978 SNPs
and the adjusted percentage change in depression severity in 1,222
SRI-treated individuals. The quantile–quantile plot showed a
uniform distribution of p-values, indicating no inflation of the test
statistic (median lambda = 1.0094; Figure 2). No SNP was
associated at the genome-wide level of significance (Figure 3).
Response to Noradrenergic Antidepressants
A linear regression tested association between 520,978 SNPs
and adjusted percentage change in depression severity in 568
NRI-treated individuals. The quantile–quantile plot showed a
uniform distribution of p-values, with no inflation of the test
statistic (median lambda = 0.9875; Figure 2). There were no
significant associations (Figure 3).
Differential Response to Serotonergic and Noradrenergic
Antidepressants
A linear regression tested the interaction between 520,978 SNPs
and antidepressant type (SRI versus NRI) in their effects on the
adjusted percentage change in depression severity among the 949
individuals randomly allocated to SRI or NRI antidepressant. The
quantile–quantile plot showed a uniform distribution of p-values,
with no inflation of the test statistic (median lambda = 1.0015;
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Figure 2). No genotype–drug interactions were detected at the
genome-wide level of significance (Figure 3).
For all four analyses, a meta-analysis of results from contrib-
uting studies also gave negative results (see Text S1, section 6).
Pathway Analysis
Pathway analysis tested whether any biological pathways had
more genes in the top 5% of genes (ranked by their most
significant SNP) than expected by chance. None of the four
analyses (response to any antidepressant, serotonergic antidepres-
sants, noradrenergic antidepressants, and differential response to
serotonergic and noradrenergic antidepressants) showed a signif-
icant excess in the number of enriched pathways, and no single
pathway was significantly enriched after correcting for multiple
testing. Full results are given in Text S1 (section 3.2).
Meta-Analysis with STAR*D
A meta-analysis tested percentage improvement in 2,897
individuals from NEWMEDS and STAR*D using over 1.1
million genotyped and imputed SNPs and found no genome-wide
significant results. A meta-analysis restricted to SRI-treated
individuals (n= 2,329) found no genome-wide significant results.
For more information see Text S1 (section 4.4).
Polygenic Scoring
Polygenic scores were calculated to test the combined effect of
multiple weak associations across the genome. Scores were created
using NEWMEDS and used to predict outcomes in STAR*D. In
the analysis that included all individuals (NEWMEDS, n= 1,790;
STAR*D, n= 1,107), there was no significant prediction across the
13 progressive p-value thresholds. In a sample restricted to SRI-
treated individuals (NEWMEDS, n= 1,222; STAR*D, n= 1,107),
there was no significant prediction from any of the 13 progressive
p-value thresholds either. Further information about the results
can be found in Text S1 (section 5.2).
Discussion
In a large pharmacogenetic analysis, including 1,790 antide-
pressant-treated individuals with MDD, none of the more than
500,000 genetic markers predicted treatment outcome after
genome-wide correction. Since our study had adequate statistical
power to detect common genetic variants with a clinically
significant predictive effect, the results suggest that single marker
prediction will not contribute to personalizing prescription of
currently available antidepressants. Increasing sample size may aid
in obtaining positive results in future studies, which may provide
Figure 2. Quantile–quantile plots for the four genome-wide analyses. (A) Analysis of the whole sample (n= 1,790); (B) analysis of SRI-treated
individuals (n=1,222); (C) analysis of NRI-treated individuals (n=568); (D) gene-by-drug interaction analysis in the randomly allocated individuals
(n=949). The shaded area is the 95% confidence interval of values expected under a uniform distribution.
doi:10.1371/journal.pmed.1001326.g002
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insight into the mechanism of the therapeutic action of antide-
pressants, even though the effect size will likely be too small to
translate into clinical applications.
The lack of genome-wide significant or even moderately strong
associations among a comprehensive list of candidate genes (details
in Text S1, section 7) puts previously reported positive results from
smaller candidate gene studies [4,35] into a sobering perspective.
The current study also fails to strengthen associations found
previously in the genome-wide association study of the GENDEP
sample [17], the largest sub-sample in the NEWMEDS consortium,
or other genome-wide pharmacogenetic studies [11,12,17]. Fur-
thermore, the current investigation fails to find a genome-wide
significant association in the largest pharmacogenetic meta-analysis
to date, which included 2,897 individuals. Pathway analysis has not
shown any enrichment for a known biological pathway. Polygenic
prediction has not found any evidence for a distributed convergent
signal between the two largest pharmacogenetic samples collected to
date. It is therefore possible that common polymorphisms will not
help predict the outcome of treatment with commonly used
antidepressants in a clinical meaningful way.
Limitations
The present study benefited from a large sample through the
combination of participants from multiple studies. This limits the
interpretation of the present results in several ways. One limitation
is the use of multiple antidepressants, each differing slightly in its
chemical structure, transporter affinity, and receptor binding
profile. Based on previous pharmacogenetic data [14], we
hypothesized the existence of common genetic predictors of
response to antidepressants with broadly defined modes of action,
such as serotonin and noradrenaline reuptake inhibition. While we
found no predictors of response to SRI or NRI types of
antidepressants, our results are compatible with the existence of
pharmacogenetic effects that are specific to a particular antide-
pressant compound. Large groups treated with the same drug may
uncover genetic predictors that were not detected in the present
study. However, the largest existing sample treated with the same
antidepressant has also failed to detect significant genetic
predictors in a genome-wide analysis [11], and it is unlikely that
even larger samples with homogeneous treatment will be collected
in the near future. The studies included in NEWMEDS also
differed in other aspects, e.g., in the depression rating scale used
and in the way participants were recruited. The adjusted change
score used as the phenotype in this study removed effects specific
to each individual contributing study. This measure was intended
to minimize the risk of spurious findings, but it could have reduced
the impact of a genuinely larger treatment effect in a particular
study. However, our aim was to detect pragmatic predictors that
generalize to multiple settings rather than effects specific to a
particular homogeneous group. It is unlikely that pharmacogenetic
predictions limited to a particular depression rating scale or to a
more homogeneous subgroup of patients would be clinically
meaningful or commercially viable. Furthermore, a meta-analysis
conducted across the individual studies provided similar results
(see Text S1, section 6). A related limitation was the smaller size of
the NRI-treated sample, meaning that only relatively strong
predictors could be identified in this arm of the study. Additional
limitations pertain to the scope of the present study. Our results
are limited to the influence of common polymorphisms on the
therapeutic effects of several monoaminergic antidepressants
under study in individuals of European ancestry. Studies in other
populations and studies of antidepressants with a non-monoam-
inergic mode of action are needed to extend the scope of
pharmacogenetic exploration.
Conclusions and Future Directions
Our study adds to the growing literature of genome-wide
pharmacogenetic studies, offering, to our knowledge, the largest
body of pharmacogenetic data available to date. The absence of
pharmacogenetic associations with clinically meaningful effect
suggests that common genetic variation is not ready to inform
personalization of treatment for depression. Future studies may
need to combine clinical, genetic, epigenetic, transcriptomic, and
proteomic information to obtain clinically meaningful prediction
of how an individual with major depression will respond to
antidepressant treatment.
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Editors’ Summary
Background. Genetic and environmental factors can
influence a person’s response to medications. Taking
advantage of the recent advancements in genetics, scientists
are working to match specific gene variations with responses
to particular medications. Knowing whether a patient is likely
to respond to a drug or have serious side effects would allow
doctors to select the best treatment up front. Right now,
there are only a handful of examples where a patient’s
version of a particular gene predicts their response to a
particular drug. Some scientists believe that there will be
many more such matches between genetic variants and
treatment responses. Others think that because the action of
most drugs is influenced by many different genes, a variant
in one of those genes is unlikely to have measurable effect in
most cases.
Why Was This Study Done? One of the areas where
patients’ responses to available drugs vary widely is severe
depression (or major depressive disorder). Prescription of an
antidepressant is often the first step in treating the disease.
However, less than half of patients get well taking the first
antidepressant prescribed. Those who don’t respond to the
first drug need to, together with their doctors, try multiple
courses of treatment to find the right drug and the right
dose for them. For some patients none of the existing drugs
work well.
To see whether genetic information could help improve the
choice of antidepressant, researchers from universities and
the pharmaceutical industry joined forces in this large study.
They examined two ways to use genetic information to
improve the treatment of depression. First, they searched all
genes for common genetic variants that could predict which
patients would not respond to the two major groups of
antidepressants (serotonin reuptake inhibitors, or SRIs, and
noradrenaline reuptake inhibitors, or NRIs). They hoped that
this would help with the development of new drugs that
could help these patients. Second, they looked for common
genetic variants in all genes that could identify patients who
responded to one of the two major groups of antidepres-
sants. Such predictors would make it possible to know which
drug to prescribe for which patient.
What Did the Researchers Do and Find? The researchers
selected 1,790 patients with severe depression who had
participated in one of several research studies; 1,222 of the
patients had been treated with an SRI, the remaining 568
with an NRI, and it was recorded how well the drugs worked
for each patient. The researchers also had a detailed picture
of the genetic make-up of each patient, with information for
over half a million genetic variants. They then looked for an
association between genetic variants and responses to
drugs.
They found not a single genetic variant that could predict
clearly whether a person would respond to antidepressants
in general, to one of the two main groups (SRIs and NRIs), or
much better to one than the other. They also didn’t find any
combination of variants in groups of genes that work
together that could predict responses. Combining their data
with those from another large study did not yield any robust
predictors either.
What Do These Findings Mean? This study was large
enough that it should have been possible to find common
genetic variants that by themselves could predict a clinically
meaningful response to SRIs and/or NRIs, had such variants
existed. The fact that the study failed to find such variants
suggests that such variants do not exist. It is still possible,
however, that variants that are less common could predict
response, or that combinations of variants could. To find
those, if they do exist, even larger studies will need to be
done.
Additional Information Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001326
N The National Institute of General Medical Sciences at the
US National Institutes of Health has a fact sheet on
personalized medicine
N PubMed Health at the US National Library of Medicine has
a page on major depressive disorder
N Wikipedia has pages on major depressive disorder and
pharmacogenetics, the study of how genetic variation
affects response to certain drugs (note that Wikipedia is a
free online encyclopedia that anyone can edit)
N The UK National Health Service has comprehensive
information pages on depression
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